Approximately 12 million children and adults in the United States have inadequately controlled asthma, many with severe asthma. In this video webcast of a satellite symposium held during CHEST 2018, Reynold Panettieri, Jr, MD, and Nicola Hanania, MD, MS, discuss the importance of and how to differentiate severe from uncontrolled asthma. They review what is known about phenotypes of severe asthma and key biomarkers. Discussion is focused on the evidence for and role of targeted biologics for severe asthma phenotypes as recommended in the 2018 Global Initiative for Asthma (GINA) guidelines. The use of a shared decision-making tool is also explored.
This activity was developed for pulmonologists, allergists, and other clinicians involved in the management of severe asthma.
Enter your information to begin.
- Definition and features
- Phenotypes and biomarkers
- GINA 2018
- Targeted biologics
- Shared decision-making
Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Director, American Lung Association
Airways Clinical Research Center
Baylor College of Medicine
Reynold A. Panettieri, Jr, MD
Vice Chancellor for Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Robert Wood Johnson Medical School
New Brunswick, New Jersey
1.50 AMA PRA Category 1 Credits™.
||December 15, 2018
||December 15, 2019
Other Healthcare Providers
This activity is supported by educational grants from AstraZeneca and GlaxoSmithKline.